Rinvoq (Upadacitinib) Mechanism of Action (MOA)
Upadacitinib is among the novel class of medicines with a unique mechanism of action (MOA). It is available by the brand name, Rinvoq that has been approved in 2019 by the FDA. Among the biological medications, it is one of the few medicines that are available as oral tablet formulations with once-daily dosing. Rinvoq Indications: … Read more